with OPEX of $25M I believe ist more like 32000 tests.
I completely agree regarding the potential for the company. The company have always suggested that they are re-writing the GOLD standard for bladder cancer. It’s non invasive and highly accurate.
I would suggest within the next 3 years there may be either a take over offer or listing on the US exchange.
However I still think a CR is coming.
I mentioned in earlier posts the following
Essentially I pick that there is 3 months before another credit raise.
If the LCD comes through PEB can recognise 3.6M USD in revenue. $5.6M NZD. That doubles Revenue for the FY!
in conjunction to that they can negotiate a payment for the previous tests completed. (17000 tests). This has been invoiced but not paid as there is no LCD. This is $20M USD worth of tests produced. I don’t for one minute believe that PEB will bet the full amount but it shows the potential.
This years test (revenue not recognised) plus back log is Almost $25M NZD.
Size of the opportunity from the KP agreement I have roughly calculated based on the NZ number of tests.
Expand
